Cardiol Therapeutics Inc
TSX:CRDL
Cardiol Therapeutics Inc
Cash from Operating Activities
Cardiol Therapeutics Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cardiol Therapeutics Inc
TSX:CRDL
|
Cash from Operating Activities
-CA$25.3m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Canopy Growth Corp
TSX:WEED
|
Cash from Operating Activities
-CA$165.8m
|
CAGR 3-Years
33%
|
CAGR 5-Years
26%
|
CAGR 10-Years
-51%
|
|
|
Aurora Cannabis Inc
TSX:ACB
|
Cash from Operating Activities
-CA$8.7m
|
CAGR 3-Years
53%
|
CAGR 5-Years
50%
|
CAGR 10-Years
-11%
|
|
|
Sundial Growers Inc
NASDAQ:SNDL
|
Cash from Operating Activities
CA$59.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Cash from Operating Activities
$19m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Cash from Operating Activities
CA$9.1m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Cardiol Therapeutics Inc
Glance View
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory therapies for cardiovascular disease (CVD). The company is headquartered in Oakville, Ontario and currently employs 11 full-time employees. The company went IPO on 2018-12-20. The firm's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.
See Also
What is Cardiol Therapeutics Inc's Cash from Operating Activities?
Cash from Operating Activities
-25.3m
CAD
Based on the financial report for Mar 31, 2025, Cardiol Therapeutics Inc's Cash from Operating Activities amounts to -25.3m CAD.
What is Cardiol Therapeutics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-21%
Over the last year, the Cash from Operating Activities growth was -14%.
You don't have any saved screeners yet